{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:05:50Z","timestamp":1793869550404,"version":"4.6.1"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11912-024-01555-0","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T07:01:41Z","timestamp":1717570901000},"page":"945-958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["From Detection to Cure \u2013 Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Joshua A.","family":"Linscott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithvi B.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijie","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Daniel","family":"Grass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Vosoughi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Zemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Poch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade J.","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"1555_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","volume":"14","author":"G Siravegna","year":"2017","unstructured":"Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531\u201348.","journal-title":"Nat Rev Clin Oncol."},{"key":"1555_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41416-021-01696-0","volume":"126","author":"M Cisneros-Villanueva","year":"2022","unstructured":"Cisneros-Villanueva M, Hidalgo-P\u00e9rez L, Rios-Romero M, Cedro-Tanda A, Ruiz-Villavicencio CA, Page K, et al. Cell-free DNA analysis in current cancer clinical trials: a review. Br J Cancer. 2022;126:391\u2013400.","journal-title":"Br J Cancer."},{"key":"1555_CR3","volume":"4","author":"AA Chaudhuri","year":"2020","unstructured":"Chaudhuri AA, Pellini B, Pejovic N, Chauhan PS, Harris PK, Szymanski JJ, et al. Emerging roles of urine-based tumor DNA analysis in bladder cancer management. JCO Precis Oncol. 2020;4:PO.20.00060.","journal-title":"JCO Precis Oncol"},{"key":"1555_CR4","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41585-023-00725-2","volume":"20","author":"KM Rose","year":"2023","unstructured":"Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, et al. Circulating and urinary tumour DNA in urothelial carcinoma \u2014 upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023;20:406\u201319.","journal-title":"Nat Rev Urol."},{"key":"1555_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin."},{"key":"1555_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","volume":"17","author":"JJ Meeks","year":"2020","unstructured":"Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA, Flaig TW, DeGraff DJ, et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat Rev Urol. 2020;17:259\u201370.","journal-title":"Nat Rev Urol."},{"key":"1555_CR7","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstr\u00f6m P-U, Choi W, et al. Bladder cancer. The Lancet. 2016;388:2796\u2013810.","journal-title":"The Lancet."},{"key":"1555_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","volume":"20","author":"M Maas","year":"2023","unstructured":"Maas M, Todenh\u00f6fer T, Black PC. Urine biomarkers in bladder cancer \u2014 current status and future perspectives. Nat Rev Urol. 2023;20:597\u2013614.","journal-title":"Nat Rev Urol."},{"key":"1555_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.eururo.2024.01.004","volume":"85","author":"JA Linscott","year":"2024","unstructured":"Linscott JA, Meeks JJ, Dyrskj\u00f8t L, Li R. The elusive horizon: biomarkers in urothelial carcinoma. Eur Urol. 2024;85:317\u20139.","journal-title":"Eur Urol."},{"key":"1555_CR10","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/cas.16097","volume":"115","author":"Y Bao","year":"2024","unstructured":"Bao Y, Zhang D, Guo H, Ma W. Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine. Cancer Sci. 2024;115:1060\u201372.","journal-title":"Cancer Sci."},{"key":"1555_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-022-01710-w","volume":"22","author":"P Stejskal","year":"2023","unstructured":"Stejskal P, Goodarzi H, Srovnal J, Hajd\u00fach M, van\u2019t Veer LJ, MJM M. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Mol Cancer. 2023;22:15.","journal-title":"Mol Cancer."},{"key":"1555_CR12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/cr.2014.44","volume":"24","author":"BK Thakur","year":"2014","unstructured":"Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 2014;24:766\u20139.","journal-title":"Cell Res."},{"key":"1555_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10555-016-9629-x","volume":"35","author":"AR Thierry","year":"2016","unstructured":"Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35:347\u201376.","journal-title":"Cancer Metastasis Rev."},{"key":"1555_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223\u201338.","journal-title":"Nat Rev Cancer."},{"key":"1555_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","volume":"124","author":"L Keller","year":"2021","unstructured":"Keller L, Belloum Y, Wikman H, Pantel K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer. 2021;124:345\u201358.","journal-title":"Br J Cancer."},{"key":"1555_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-019-1770-3","volume":"10","author":"I Alborelli","year":"2019","unstructured":"Alborelli I, Generali D, Jermann P, Cappelletti MR, Ferrero G, Scaggiante B, et al. Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. Cell Death Dis. 2019;10:1\u201311.","journal-title":"Cell Death Dis."},{"key":"1555_CR17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.4161\/cbt.5.10.3240","volume":"5","author":"AA Kamat","year":"2006","unstructured":"Kamat AA, Bischoff FZ, Dang D, Baldwin M, Han LY, Lin YG, et al. Circulating cell-free DNA: A novel biomarker for response to therapy in ovarian carcinoma. Cancer Biology & Therapy. 2006;5:1369\u201374.","journal-title":"Cancer Biology & Therapy."},{"key":"1555_CR18","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24\u20134.","journal-title":"Sci Transl Med"},{"key":"1555_CR19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.euo.2021.04.005","volume":"4","author":"EA Green","year":"2021","unstructured":"Green EA, Li R, Albiges L, Choueiri TK, Freedman M, Pal S, et al. Clinical utility of cell-free and circulating tumor DNA in kidney and bladder cancer: a critical review of current literature. Eur Urol Oncol. 2021;4:893\u2013903.","journal-title":"Eur Urol Oncol."},{"key":"1555_CR20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985\u201390.","journal-title":"Nat Med."},{"key":"1555_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.gene.2016.06.033","volume":"590","author":"W Yao","year":"2016","unstructured":"Yao W, Mei C, Nan X, Hui L. Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: A qualitative study. Gene. 2016;590:142\u20138.","journal-title":"Gene."},{"key":"1555_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4143\/crt.2022.1026","volume":"55","author":"H Kim","year":"2023","unstructured":"Kim H, Park KU. Clinical circulating tumor DNA testing for precision oncology. Cancer Research and Treatment\u00a0: Official Journal of Korean Cancer Association. 2023;55:351.","journal-title":"Cancer Research and Treatment\u00a0: Official Journal of Korean Cancer Association."},{"key":"1555_CR23","first-page":"67","volume":"3","author":"GD Sorenson","year":"1994","unstructured":"Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994;3:67\u201371.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"1555_CR24","first-page":"2689","volume":"5","author":"G Sozzi","year":"1999","unstructured":"Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res. 1999;5:2689\u201392.","journal-title":"Clin Cancer Res."},{"key":"1555_CR25","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ijc.10526","volume":"100","author":"T Lecomte","year":"2002","unstructured":"Lecomte T, Berger A, Zinzindohou\u00e9 F, Micard S, Landi B, Blons H, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer. 2002;100:542\u20138.","journal-title":"Int J Cancer."},{"key":"1555_CR26","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1073\/pnas.1133470100","volume":"100","author":"D Dressman","year":"2003","unstructured":"Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003;100:8817\u201322.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1555_CR27","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3324\/haematol.2016.145888","volume":"101","author":"C Baer","year":"2016","unstructured":"Baer C, Kern W, Koch S, Nadarajah N, Schindela S, Meggendorfer M, et al. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia. Haematologica. 2016;101:830\u20138.","journal-title":"Haematologica."},{"key":"1555_CR28","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8:1324.","journal-title":"Nat Commun."},{"key":"1555_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nmeth.1419","volume":"7","author":"L Mamanova","year":"2010","unstructured":"Mamanova L, Coffey AJ, Scott CE, Kozarewa I, Turner EH, Kumar A, et al. Target-enrichment strategies for next-generation sequencing. Nat Methods. 2010;7:111\u20138.","journal-title":"Nat Methods."},{"key":"1555_CR30","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1158\/1078-0432.CCR-22-2177","volume":"29","author":"AA Davis","year":"2023","unstructured":"Davis AA, Luo J, Zheng T, Dai C, Dong X, Tan L, et al. Genomic complexity predicts resistance to endocrine therapy and CDK4\/6 inhibition in hormone receptor\u2013positive (HR+)\/HER2-negative metastatic breast cancer. Clin Cancer Res. 2023;29:1719\u201329.","journal-title":"Clin Cancer Res."},{"key":"1555_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nbt.3520","volume":"34","author":"AM Newman","year":"2016","unstructured":"Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34:547\u201355.","journal-title":"Nat Biotechnol."},{"key":"1555_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13148-022-01382-9","volume":"14","author":"Q Wang","year":"2022","unstructured":"Wang Q, Xiong F, Wu G, Liu W, Chen J, Wang B, et al. Gene body methylation in cancer: Molecular mechanisms and clinical applications. Clin Epigenetics. 2022;14:154.","journal-title":"Clin Epigenetics."},{"key":"1555_CR33","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","volume":"37","author":"A Nishiyama","year":"2021","unstructured":"Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends in Genetics. 2021;37:1012\u201327.","journal-title":"Trends in Genetics."},{"key":"1555_CR34","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/curroncol31010033","volume":"31","author":"DB Sacdalan","year":"2024","unstructured":"Sacdalan DB, Ul Haq S, Lok BH. Plasma cell-free tumor methylome as a biomarker in solid tumors: biology and applications. Curr Oncol. 2024;31:482\u2013500.","journal-title":"Curr Oncol."},{"key":"1555_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.canlet.2017.03.029","volume":"396","author":"A Van Tongelen","year":"2017","unstructured":"Van Tongelen A, Loriot A, De Smet C. Oncogenic roles of DNA hypomethylation through the activation of cancer-germline genes. Cancer Lett. 2017;396:130\u20137.","journal-title":"Cancer Lett."},{"key":"1555_CR36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","volume":"563","author":"SY Shen","year":"2018","unstructured":"Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563:579\u201383.","journal-title":"Nature."},{"key":"1555_CR37","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/1538-7445.AM2023-1030","volume":"83","author":"BH Park","year":"2023","unstructured":"Park BH, Shen SY, Min J, Fleshner N, Knox J, May T, et al. Abstract 1030: Development of a genome-wide methylome enrichment platform for multi-cancer early detection (MCED). Cancer Res. 2023;83:1030.","journal-title":"Cancer Res"},{"key":"1555_CR38","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41416-022-01776-9","volume":"127","author":"M Garc\u00eda-Pardo","year":"2022","unstructured":"Garc\u00eda-Pardo M, Makarem M, Li JJN, Kelly D, Leighl NB. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. Br J Cancer. 2022;127:592\u2013602.","journal-title":"Br J Cancer."},{"key":"1555_CR39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","volume":"580","author":"JJ Chabon","year":"2020","unstructured":"Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020;580:245\u201351.","journal-title":"Nature."},{"key":"1555_CR40","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer. N Engl J Med. 2019;380:1929\u201340.","journal-title":"N Engl J Med"},{"key":"1555_CR41","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.2021.39.15_suppl.3506","volume":"39","author":"A Sartore-Bianchi","year":"2021","unstructured":"Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Fenocchio E, et al. Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial. JCO. 2021;39:3506\u20136.","journal-title":"JCO."},{"key":"1555_CR42","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen E, Birkenkamp-Demtr\u00f6der K, Sethi H, Shchegrova S, Salari R, Nordentoft I, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. JCO. 2019;37:1547\u201357.","journal-title":"JCO."},{"key":"1555_CR43","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41416-021-01648-8","volume":"126","author":"KS Shohdy","year":"2022","unstructured":"Shohdy KS, Villamar DM, Cao Y, Trieu J, Price KS, Nagy R, et al. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. Br J Cancer. 2022;126:430\u20139.","journal-title":"Br J Cancer."},{"key":"1555_CR44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2023.09.017","volume":"85","author":"HL Huelster","year":"2024","unstructured":"Huelster HL, Gould B, Schiftan EA, Camperlengo L, Davaro F, Rose KM, et al. Novel use of circulating tumor DNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma. Eur Urol. 2024;85:283\u201392.","journal-title":"Eur Urol."},{"key":"1555_CR45","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1126\/science.101.2629.519","volume":"101","author":"GN Papanicolaou","year":"1945","unstructured":"Papanicolaou GN, Marshall VF. Urine Sediment smears as a diagnostic procedure in cancers of the urinary tract. Science. 1945;101:519\u201320.","journal-title":"Science."},{"key":"1555_CR46","doi-asserted-by":"publisher","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","volume":"33","author":"FA Yafi","year":"2015","unstructured":"Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 2015;33:66.e25\u2013-31.","journal-title":"Urol Oncol"},{"key":"1555_CR47","first-page":"882","volume":"5","author":"MD Reid","year":"2012","unstructured":"Reid MD, Osunkoya AO, Siddiqui MT, Looney SW. Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement. Int J Clin Exp Pathol. 2012;5:882\u201391.","journal-title":"Int J Clin Exp Pathol."},{"key":"1555_CR48","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000446270","volume":"60","author":"GA Barkan","year":"2016","unstructured":"Barkan GA, Wojcik EM, Nayar R, Savic-Prince S, Quek ML, Kurtycz DFI, et al. The Paris system for reporting urinary cytology: The quest to develop a standardized terminology. Acta Cytol. 2016;60:185\u201397.","journal-title":"Acta Cytol."},{"key":"1555_CR49","first-page":"120","volume":"10","author":"SF Shariat","year":"2008","unstructured":"Shariat SF, Karam JA, Lotan Y, Karakiewizc PI. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol. 2008;10:120\u201335.","journal-title":"Rev Urol."},{"key":"1555_CR50","first-page":"2511","volume":"4","author":"R Kinders","year":"1998","unstructured":"Kinders R, Jones T, Root R, Bruce C, Murchison H, Corey M, et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res. 1998;4:2511\u201320.","journal-title":"Clin Cancer Res."},{"key":"1555_CR51","doi-asserted-by":"crossref","unstructured":"Miyake M, Goodison S, Rizwani W, Ross S, Grossman HB, Rosser CJ. Urinary BTA: Indicator of bladder cancer or of hematuria. World J Urol. 2012;30:869\u2013873.","DOI":"10.1007\/s00345-012-0935-9"},{"key":"1555_CR52","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1464-410X.2007.07287.x","volume":"101","author":"B Schmitz-Dr\u00e4ger","year":"2008","unstructured":"Schmitz-Dr\u00e4ger B, Tirsar LA, Schmitz-Dr\u00e4ger C, D\u00f6rsam J, Bismarck E, Ebert T. Immunocytology in the assessment of patients with painless gross haematuria. BJU Int. 2008;101:455\u20138.","journal-title":"BJU Int."},{"key":"1555_CR53","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/S0022-5347(05)67104-2","volume":"164","author":"KC Halling","year":"2000","unstructured":"Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000;164:1768\u201375.","journal-title":"J Urol."},{"key":"1555_CR54","doi-asserted-by":"crossref","unstructured":"Chou R, Buckley D, Fu R, Gore JL, Gustafson K, Griffin J, Grusing S, Selph S. Emerging approaches to diagnosis and treatment of non\u2013muscle-invasive bladder cancer. Agency for Healthcare Research and Quality (US). 2015;","DOI":"10.1002\/cncr.29843"},{"key":"1555_CR55","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.21037\/tau-20-1207","volume":"10","author":"T Nagai","year":"2021","unstructured":"Nagai T, Naiki T, Etani T, Iida K, Noda Y, Shimizu N, et al. UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives. Transl Androl Urol. 2021;10:1908\u201317.","journal-title":"Transl Androl Urol."},{"key":"1555_CR56","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nrurol.2014.245","volume":"11","author":"S Daneshmand","year":"2014","unstructured":"Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014;11:589\u201396.","journal-title":"Nat Rev Urol."},{"key":"1555_CR57","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/1756287212454181","volume":"4","author":"B Geavlete","year":"2012","unstructured":"Geavlete B, Jecu M, Multescu R, Geavlete P. Narrow-band imaging cystoscopy in non-muscle-invasive bladder cancer: a prospective comparison to the standard approach. Ther Adv Urol. 2012;4:211\u20137.","journal-title":"Ther Adv Urol."},{"key":"1555_CR58","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200092","volume":"1","author":"R Heer","year":"2022","unstructured":"Heer R, Lewis R, Vadiveloo T, Yu G, Mariappan P, Cresswell J, et al. A randomized Trial of PHOTOdynamic surgery in non-muscle-invasive bladder cancer. NEJM Evid. 2022;1:EVIDoa2200092.","journal-title":"NEJM Evid"},{"key":"1555_CR59","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/CU9.0000000000000142","volume":"16","author":"EM Cahill","year":"2022","unstructured":"Cahill EM, Chua K, Doppalapudi SK, Ghodoussipour S. The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer. Curr Urol. 2022;16:121\u20136.","journal-title":"Curr Urol."},{"key":"1555_CR60","unstructured":"Gontero P, Comperat E, Dominguez Escrig JL, Liedberg F, Mariappan P, Masson-Lecomte A, et al. EAU Guidelines on Non-muscle -invasive Bladder Cancer (TaT1 and CIS) EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023."},{"key":"1555_CR61","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"JN Weinstein","year":"2014","unstructured":"Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, McConkey D, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315\u201322.","journal-title":"Nature."},{"key":"1555_CR62","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"\u2022 Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540\u2013556.e25.\u00a0Landmark study providing comprehensive molecular profiling of 412 muscle invasive bladder cancer patients with no prior neoadjuvant treatment.","journal-title":"Cell"},{"key":"1555_CR63","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94\u2013101.","journal-title":"Nature."},{"key":"1555_CR64","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y, Sj\u00f6dahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420\u201333.","journal-title":"Eur Urol."},{"key":"1555_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013821","volume":"5","author":"LC Kompier","year":"2010","unstructured":"Kompier LC, Lurkin I, van der Aa MNM, van Rhijn BWG, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010;5:e13821.","journal-title":"PLoS One."},{"key":"1555_CR66","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","volume":"72","author":"EJ Pietzak","year":"2017","unstructured":"Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S, et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur Urol. 2017;72:952\u20139.","journal-title":"Eur Urol."},{"key":"1555_CR67","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard J, Lamy P, Nordentoft I, Algaba F, H\u00f8yer S, Ulh\u00f8i BP, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30:27\u201342.","journal-title":"Cancer Cell."},{"key":"1555_CR68","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"\u2022 Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtr\u00f6der K, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12:2301. State of the art molecular profiling in non-muscle invasive bladder cancer patients revealing 4 subtypes with differing genomic expression patterns, corresponding immune infiltration, and varying risks of progression.","journal-title":"Nat Commun."},{"key":"1555_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231058","volume":"15","author":"E Augustus","year":"2020","unstructured":"Augustus E, Van Casteren K, Sorber L, van Dam P, Roeyen G, Peeters M, et al. The art of obtaining a high yield of cell-free DNA from urine. PLoS One. 2020;15:e0231058.","journal-title":"PLoS One."},{"key":"1555_CR70","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.clinbiochem.2017.02.017","volume":"50","author":"THT Cheng","year":"2017","unstructured":"\u2022 Cheng THT, Jiang P, Tam JCW, Sun X, Lee W-S, Yu SCY, et al. Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA. Clinical Biochemistry. 2017;50:496\u2013501.\u00a0Demonstration of DNA methylation aberrations in 46 localized bladder cancer cases and ability to detect and diagnose patients with shallow depth whole genome bisulfite sequencing.","journal-title":"Clinical Biochemistry."},{"key":"1555_CR71","doi-asserted-by":"crossref","unstructured":"Markus H, Zhao J, Contente-Cuomo T, Stephens MD, Raupach E, Odenheimer-Bergman A, et al. Analysis of recurrently protected genomic regions in cell-free DNA found in urine. Sci Transl Med. 2021;13:eaaz3088.","DOI":"10.1126\/scitranslmed.aaz3088"},{"key":"1555_CR72","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/clinchem\/hvaa325","volume":"67","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Cheng SH, Ding SC, Heung MMS, Xie T, Cheng THT, et al. Jagged ends of urinary cell-free DNA: characterization and feasibility assessment in bladder cancer detection. Clin Chem. 2021;67:621\u201330.","journal-title":"Clin Chem"},{"key":"1555_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1010262","volume":"18","author":"M Chen","year":"2022","unstructured":"Chen M, Chan RWY, Cheung PPH, Ni M, Wong DKL, Zhou Z, et al. Fragmentomics of urinary cell-free DNA in nuclease knockout mouse models. PLOS Genetics. 2022;18:e1010262.","journal-title":"PLOS Genetics."},{"key":"1555_CR74","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","volume":"70","author":"K Birkenkamp-Demtr\u00f6der","year":"2016","unstructured":"\u2022\u2022 Birkenkamp-Demtr\u00f6der K, Nordentoft I, Christensen E, H\u00f8yer S, Reinert T, Vang S, et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol. 2016;70:75\u201382.\u00a0Landmark study demonstrating utDNA is not only reflective of tumor of original, but that it is detected more than ctDNA, especially in early disease. Utilizing personalized assays they detect utDNA prior to disease recurrence or progression in 12 of 12 patients.","journal-title":"Eur Urol."},{"key":"1555_CR75","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","volume":"71","author":"E Christensen","year":"2017","unstructured":"Christensen E, Birkenkamp-Demtr\u00f6der K, Nordentoft I, H\u00f8yer S, van der Keur K, van Kessel K, et al. Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer. Eur Urol. 2017;71:961\u20139.","journal-title":"Eur Urol"},{"key":"1555_CR76","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/JU.0000000000001878","volume":"206","author":"R Zhang","year":"2021","unstructured":"\u2022\u2022 Zhang R, Zang J, Xie F, Zhang Y, Wang Y, Jing Y, et al. Urinary molecular pathology for patients with newly diagnosed urothelial bladder cancer. J Urol. 2021;206:873\u201384.\u00a0Achieved 99.1% diagnostic accuracy in localized bladder cancer cases with hybrid capture NGS utilizing a tumor informed approach and personalized assays.","journal-title":"J Urol"},{"key":"1555_CR77","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3389\/fonc.2019.01266","volume":"9","author":"U Satyal","year":"2019","unstructured":"Satyal U, Srivastava A, Abbosh PH. Urine biopsy\u2014liquid gold for molecular detection and surveillance of bladder cancer. Front Oncol. 2019;9:1266.","journal-title":"Front Oncol."},{"key":"1555_CR78","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1111\/cas.14155","volume":"110","author":"Y Hirotsu","year":"2019","unstructured":"Hirotsu Y, Yokoyama H, Amemiya K, Hagimoto T, Daimon H, Hosaka K, et al. Genomic profile of urine has high diagnostic sensitivity compared to cytology in non-invasive urothelial bladder cancer. Cancer Sci. 2019;110:3235\u201343.","journal-title":"Cancer Sci."},{"key":"1555_CR79","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40169-020-0257-2","volume":"9","author":"Z Ou","year":"2020","unstructured":"Ou Z, Li K, Yang T, Dai Y, Chandra M, Ning J, et al. Detection of bladder cancer using urinary cell-free DNA and cellular DNA. Clin Transl Med. 2020;9:4.","journal-title":"Clin Transl Med"},{"key":"1555_CR80","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","volume":"9","author":"JC Dudley","year":"2019","unstructured":"\u2022\u2022 Dudley JC, Schroers-Martin J, Lazzareschi DV, Shi WY, Chen SB, Esfahani MS, et al. Detection and surveillance of bladder cancer using urine tumor DNA. Cancer Discov. 2019;9:500\u20139.\u00a0One of the earliest studies to demonstrate the value of utDNA in a large patient cohort. The strengths include using TCGA to inform genes for detecting tumors and censoring mutations frequently detect in healthy patients. Additionally, the use both a tumor-na\u00efve and tumor-informed approach to show how deep sequencing of targeted mutations enhances sensitivity.","journal-title":"Cancer Discov"},{"key":"1555_CR81","first-page":"35","volume":"8","author":"M Utting","year":"2002","unstructured":"Utting M, Werner W, Dahse R, Schubert J, Junker K. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin Cancer Res. 2002;8:35\u201340.","journal-title":"Clin Cancer Res"},{"key":"1555_CR82","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.urolonc.2012.07.013","volume":"31","author":"V Casadio","year":"2013","unstructured":"Casadio V, Calistri D, Tebaldi M, Bravaccini S, Gunelli R, Martorana G, et al. Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: Preliminary data. Urol Oncol: Semin Orig Investigs. 2013;31:1744\u201350.","journal-title":"Urol Oncol: Semin Orig Investigs."},{"key":"1555_CR83","doi-asserted-by":"publisher","first-page":"12428","DOI":"10.18632\/oncotarget.2660","volume":"5","author":"K Wang","year":"2014","unstructured":"Wang K, Liu T, Ge N, Liu L, Yuan X, Liu J, et al. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR. Oncotarget. 2014;5:12428\u201339.","journal-title":"Oncotarget."},{"key":"1555_CR84","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4111\/icu.2016.57.2.106","volume":"57","author":"Y-H Kim","year":"2016","unstructured":"Kim Y-H, Yan C, Lee I-S, Piao X-M, Byun YJ, Jeong P, et al. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer. Investig Clin Urol. 2016;57:106\u201312.","journal-title":"Investig Clin Urol."},{"key":"1555_CR85","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/ejhg.2015.281","volume":"24","author":"FS Togneri","year":"2016","unstructured":"Togneri FS, Ward DG, Foster JM, Devall AJ, Wojtowicz P, Alyas S, et al. Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. Eur J Hum Genet. 2016;24:1167\u201374.","journal-title":"Eur J Hum Genet."},{"key":"1555_CR86","doi-asserted-by":"publisher","first-page":"5554","DOI":"10.1038\/s41598-017-05623-3","volume":"7","author":"KM Patel","year":"2017","unstructured":"Patel KM, van der Vos KE, Smith CG, Mouliere F, Tsui D, Morris J, et al. Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer. Sci Rep. 2017;7:5554.","journal-title":"Sci Rep."},{"key":"1555_CR87","doi-asserted-by":"publisher","first-page":"14354","DOI":"10.18632\/oncotarget.24436","volume":"9","author":"WT Kim","year":"2018","unstructured":"Kim WT, Kim YH, Jeong P, Seo S-P, Kang H-W, Kim Y-J, et al. Urinary cell-free nucleic acid IQGAP3: a new non-invasive diagnostic marker for bladder cancer. Oncotarget. 2018;9:14354\u201365.","journal-title":"Oncotarget."},{"key":"1555_CR88","doi-asserted-by":"publisher","first-page":"14707","DOI":"10.1038\/s41598-018-32900-6","volume":"8","author":"DH Lee","year":"2018","unstructured":"Lee DH, Yoon H, Park S, Kim JS, Ahn Y-H, Kwon K, et al. Urinary exosomal and cell-free DNA detects somatic mutation and copy number alteration in urothelial carcinoma of bladder. Sci Rep. 2018;8:14707.","journal-title":"Sci Rep."},{"key":"1555_CR89","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ebiom.2019.05.004","volume":"44","author":"PH Avogbe","year":"2019","unstructured":"Avogbe PH, Manel A, Vian E, Durand G, Forey N, Voegele C, et al. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. eBioMedicine. 2019;44:431\u20138.","journal-title":"eBioMedicine."},{"key":"1555_CR90","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1373\/clinchem.2018.301341","volume":"65","author":"THT Cheng","year":"2019","unstructured":"Cheng THT, Jiang P, Teoh JYC, Heung MMS, Tam JCW, Sun X, et al. Noninvasive detection of bladder cancer by shallow-depth genome-wide bisulfite sequencing of urinary cell-free DNA for methylation and copy number profiling. Clin Chem. 2019;65:927\u201336.","journal-title":"Clin Chem."},{"key":"1555_CR91","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3389\/fonc.2020.00755","volume":"10","author":"Y Hayashi","year":"2020","unstructured":"Hayashi Y, Fujita K, Matsuzaki K, Eich M-L, Tomiyama E, Matsushita M, et al. Clinical significance of hotspot mutation analysis of urinary cell-free DNA in urothelial bladder cancer. Front Oncol. 2020;10:755.","journal-title":"Front Oncol."},{"key":"1555_CR92","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clinbiochem.2018.11.009","volume":"64","author":"S Stasik","year":"2019","unstructured":"Stasik S, Salomo K, Heberling U, Froehner M, Sommer U, Baretton GB, et al. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer. Clil Biochem. 2019;64:60\u20133.","journal-title":"Clil Biochem."},{"key":"1555_CR93","doi-asserted-by":"publisher","first-page":"e704","DOI":"10.1016\/j.clgc.2019.04.001","volume":"17","author":"Y Xu","year":"2019","unstructured":"Xu Y, Kim Y-H, Jeong P, Piao X-M, Byun YJ, Seo SP, et al. Urinary cell-free DNA IQGAP3\/BMP4 ratio as a prognostic marker for non\u2013muscle-invasive bladder cancer. Clin Genitourin Cancer. 2019;17:e704\u201311.","journal-title":"Clin Genitourin Cancer."},{"key":"1555_CR94","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1373\/clinchem.2019.309633","volume":"66","author":"G Ge","year":"2020","unstructured":"Ge G, Peng D, Guan B, Zhou Y, Gong Y, Shi Y, et al. Urothelial carcinoma detection based on copy number profiles of urinary cell-free DNA by shallow whole-genome sequencing. Clin Chem. 2020;66:188\u201398.","journal-title":"Clin Chem"},{"key":"1555_CR95","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3390\/cancers12040859","volume":"12","author":"AE Hentschel","year":"2020","unstructured":"Hentschel AE, Nieuwenhuijzen JA, Bosschieter J, van Splunter AP, Lissenberg-Witte BI, van der Voorn JP, et al. Comparative analysis of urine fractions for optimal bladder cancer detection using DNA methylation markers. Cancers. 2020;12:859.","journal-title":"Cancers."},{"key":"1555_CR96","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.3390\/cancers12123541","volume":"12","author":"MI Hosen","year":"2020","unstructured":"Hosen MI, Forey N, Durand G, Voegele C, Bilici S, Avogbe PH, et al. Development of sensitive droplet digital PCR assays for detecting urinary TERT promoter mutations as non-invasive biomarkers for detection of urothelial cancer. Cancers. 2020;12:3541.","journal-title":"Cancers."},{"key":"1555_CR97","doi-asserted-by":"publisher","first-page":"737.e1","DOI":"10.1016\/j.urolonc.2020.05.012","volume":"38","author":"JJG Pritchard","year":"2020","unstructured":"Pritchard JJG, Hamilton G, Hurst CD, Fraser S, Orange C, Knowles MA, et al. Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays. Urol Oncol: Semin Orig Investig. 2020;38:737.e1\u2013737.e10.","journal-title":"Urol Oncol: Semin Orig Investig"},{"key":"1555_CR98","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.21037\/tau-19-774","volume":"9","author":"C Zhao","year":"2020","unstructured":"Zhao C, Pan Y, Wang Y, Li Y, Han W, Lu L, et al. A novel cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology for bladder cancer non-invasive detection in urine. Transl Androl Urol. 2020;9:1222\u201331.","journal-title":"Transl Androl Urol."},{"key":"1555_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003732","volume":"18","author":"PS Chauhan","year":"2021","unstructured":"Chauhan PS, Chen K, Babbra RK, Feng W, Pejovic N, Nallicheri A, et al. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. PLOS Medicine. 2021;18:e1003732.","journal-title":"PLOS Medicine."},{"key":"1555_CR100","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.32143","volume":"7","author":"SU Springer","year":"2018","unstructured":"Springer SU, Chen C-H, Rodriguez Pena MDC, Li L, Douville C, Wang Y, et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife. 2018;7:e32143.","journal-title":"Elife."},{"key":"1555_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1008","volume":"12","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Ju L, Qian K, Jin W, Wang G, Zhao Y, et al. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study. Clin Transl Med. 2022;12:e1008.","journal-title":"Clin Transl Med."},{"key":"1555_CR102","doi-asserted-by":"publisher","first-page":"e16588","DOI":"10.1200\/JCO.2023.41.16_suppl.e16588","volume":"41","author":"X Chen","year":"2023","unstructured":"\u2022 Chen X, Liu Z, Zhou L, Fan J, Ruan W, Wang H, et al. UriFind assay and association with whole course management of urothelial carcinoma in a large multicentric, prospective China cohort. JCO. 2023;41:e16588\u20138.\u00a0Validation study of UriFind assay. Includes 931 patients spanning from diagnosis to surveillance.","journal-title":"JCO."},{"key":"1555_CR103","unstructured":"\u2022\u2022 Salari K, Sundi D, Lee JJ, Wu S, Wu C-L, DiFiore G, et al. Development and multicenter case\u2013control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk-prediction. Clin Cancer Res. 2023:OF1\u201313.\u00a0Multi-institutional trial evaluating 60-gene NGS whole urine assay (utDNA and exfoliated cells) in diagnosis and surveillance. In validation the UroAmp assay detected all HG and MIBC cases with an overall 99% NPV suggesting potential utility in diagnosis."},{"key":"1555_CR104","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-23-0513","volume":"29","author":"R Zhang","year":"2023","unstructured":"Zhang R, Zang J, Jin D, Xie F, Shahatiaili A, Wu G, et al. Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer. Clinical Cancer Research. 2023;29:4040\u20136.","journal-title":"Clinical Cancer Research."},{"key":"1555_CR105","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","volume":"29","author":"E Christensen","year":"2023","unstructured":"\u2022 Christensen E, Nordentoft I, Birkenkamp-Demtr\u00f6der K, Elb\u00e6k SK, Lindskrog SV, Taber A, et al. Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer. Clin Cancer Res. 2023;29:1582\u201391.\u00a0One of the definitive studies in utDNA, the authors demonstrate increased sensitivity for detecting bladder cancer with utDNA compared to ctDNA. In addition, level correlate with treatment response. For 92 patients with MIBC who received NAC, decrease in utDNA level was associated with treatment response. Patients who cleared utDNA and ctDNA after consolidative surgery did not have any cases of recurrence in follow-up.","journal-title":"Clin Cancer Res"},{"key":"1555_CR106","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.2005.03.163","volume":"23","author":"JWF Catto","year":"2005","unstructured":"Catto JWF, Azzouzi A-R, Rehman I, Feeley KM, Cross SS, Amira N, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. JCO. 2005;23:2903\u201310.","journal-title":"JCO."},{"key":"1555_CR107","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semcancer.2017.08.004","volume":"51","author":"A Chatterjee","year":"2018","unstructured":"Chatterjee A, Rodger EJ, Eccles MR. Epigenetic drivers of tumourigenesis and cancer metastasis. Semin Cancer Biol. 2018;51:149\u201359.","journal-title":"Semin Cancer Biol."},{"key":"1555_CR108","doi-asserted-by":"publisher","first-page":"603.e1","DOI":"10.1016\/j.urolonc.2020.01.007","volume":"38","author":"T Hermanns","year":"2020","unstructured":"Hermanns T, Savio AJ, Olkhov-Mitsel E, Mari A, Wettstein MS, Saba K, et al. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. Urol Oncol: Semin Orig Investig. 2020;38:603.e1\u20137.","journal-title":"Urol Oncol: Semin Orig Investig"},{"key":"1555_CR109","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.3390\/ijms21186542","volume":"21","author":"M Mancini","year":"2020","unstructured":"Mancini M, Righetto M, Zumerle S, Montopoli M, Zattoni F. The bladder EpiCheck test as a non-invasive tool based on the identification of DNA methylation in bladder cancer cells in the urine: a review of published evidence. Int J Mol Sci. 2020;21:6542.","journal-title":"Int J Mol Sci."},{"key":"1555_CR110","doi-asserted-by":"publisher","first-page":"6278","DOI":"10.1172\/JCI139597","volume":"130","author":"X Chen","year":"2020","unstructured":"\u2022\u2022 Chen X, Zhang J, Ruan W, Huang M, Wang C, Wang H, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J Clin Invest. 2020;130:6278\u201389.\u00a0Demonstration of utMeMa assay and ability to diagnosis most patients with detection of only 2 methylation markers. This finding was validated in a larger cohort and led to development of the UriFind assay.","journal-title":"J Clin Invest."},{"key":"1555_CR111","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13148-022-01240-8","volume":"14","author":"AE Hentschel","year":"2022","unstructured":"Hentschel AE, Beijert IJ, Bosschieter J, Kauer PC, Vis AN, Lissenberg-Witte BI, et al. Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation. Clin Epigenetics. 2022;14:19.","journal-title":"Clin Epigenetics."},{"key":"1555_CR112","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.3390\/jcm11195827","volume":"11","author":"VT Bicocca","year":"2022","unstructured":"Bicocca VT, Phillips KG, Fischer DS, Caruso VM, Goudarzi M, Garcia-Ransom M, et al. Urinary comprehensive genomic profiling correlates urothelial carcinoma mutations with clinical risk and efficacy of intervention. JCM. 2022;11:5827.","journal-title":"JCM."},{"key":"1555_CR113","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.urology.2017.07.016","volume":"108","author":"K Koo","year":"2017","unstructured":"Koo K, Zubkoff L, Sirovich BE, Goodney PP, Robertson DJ, Seigne JD, et al. The burden of cystoscopic bladder cancer surveillance: anxiety, discomfort, and patient preferences for decision making. Urology. 2017;108:122\u20138.","journal-title":"Urology."},{"key":"1555_CR114","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3233\/BLC-189035","volume":"4","author":"EM Messing","year":"2018","unstructured":"Messing EM. Financial toxicity of having bladder cancer. Bladder Cancer. 2018;4:351\u20132.","journal-title":"Bladder Cancer."},{"key":"1555_CR115","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.eururo.2018.06.024","volume":"74","author":"Z Klaassen","year":"2018","unstructured":"Klaassen Z, Kamat AM, Kassouf W, Gontero P, Villavicencio H, Bellmunt J, et al. Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations. Eur Urol. 2018;74:597\u2013608.","journal-title":"Eur Urol."},{"key":"1555_CR116","doi-asserted-by":"publisher","first-page":"LBA445","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA445","volume":"41","author":"KM Rose","year":"2023","unstructured":"Rose KM, Murthy P, Gould B, Huelster HL, Davaro F, Du P, et al. Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non\u2013muscle-invasive bladder cancer: A prospective study. JCO. 2023;41:LBA445\u20135.","journal-title":"JCO."},{"key":"1555_CR117","doi-asserted-by":"publisher","first-page":"247","DOI":"10.48083\/WJMB7232","volume":"4","author":"PB Murthy","year":"2023","unstructured":"Murthy PB, Gould B, Davaro F, Du P, Camperlengo L, Naidu S, et al. Utilizing cell-free urinary and plasma tumor dna to predict pathologic stage at radical cystectomy. Soc Int Urol J. 2023;4:247\u201356.","journal-title":"Soc Int Urol J."},{"key":"1555_CR118","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2023.07.014","volume":"85","author":"T Strandgaard","year":"2024","unstructured":"\u2022 Strandgaard T, Nordentoft I, Birkenkamp-Demtr\u00f6der K, Salminen L, Prip F, Rasmussen J, et al. Field cancerization is associated with tumor development, T-cell exhaustion, and clinical outcomes in bladder cancer. Eur Urol. 2024;85:82\u201392.\u00a0Thorough description of bladder cancer \"field cancerization\" and discussion of challenges facing utDNA and all deep sequencing approaches as limits of detection allow for measurement of low levels of alterations present in altered, but pathologically benign cells.","journal-title":"Eur Urol."},{"key":"1555_CR119","doi-asserted-by":"publisher","first-page":"16642","DOI":"10.1038\/s41598-022-21158-8","volume":"12","author":"Y Hayashi","year":"2022","unstructured":"Hayashi Y, Fujita K, Sakai K, Adomi S, Banno E, Nojima S, et al. Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer. Sci Rep. 2022;12:16642.","journal-title":"Sci Rep."},{"key":"1555_CR120","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1126\/science.aba8347","volume":"370","author":"ARJ Lawson","year":"2020","unstructured":"\u2022 Lawson ARJ, Abascal F, Coorens THH, Hooks Y, O\u2019Neill L, Latimer C, et al. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science. 2020;370:75\u201382.\u00a0One of two studies highlighting that mutations often viewed as driver mutations in bladder cancer occur in urothelium of non-diseased patients. This suggests many mutations alone are not sufficient for initiation of cancer and development is a complex landscape involving genomic mutations and epigenetic dysregulation.","journal-title":"Science."},{"key":"1555_CR121","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1126\/science.aba7300","volume":"370","author":"R Li","year":"2020","unstructured":"\u2022 Li R, Du Y, Chen Z, Xu D, Lin T, Jin S, et al. Macroscopic somatic clonal expansion in morphologically normal human urothelium. Science. 2020;370:82\u20139.\u00a0One of two studies highlighting that mutations often viewed as driver mutations in bladder cancer occur in urothelium of non-diseased patients. This suggests many mutations alone are not sufficient for initiation of cancer and development is a complex landscape involving genomic mutations and epigenetic dysregulation.","journal-title":"Science."},{"key":"1555_CR122","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41467-024-45778-y","volume":"15","author":"MU Ahsan","year":"2024","unstructured":"Ahsan MU, Gouru A, Chan J, Zhou W, Wang K. A signal processing and deep learning framework for methylation detection using Oxford Nanopore sequencing. Nat Commun. 2024;15:1448.","journal-title":"Nat Commun."}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01555-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-024-01555-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01555-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T05:15:33Z","timestamp":1722834933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-024-01555-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":122,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1555"],"URL":"https:\/\/doi.org\/10.1007\/s11912-024-01555-0","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"20 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive support from any organization for the submitted work. Financial conflicts of interest: Joshua Linscott, Hiroko Miyagi, Prithvi Murthy, Sijie Yao, G. Daniel Grass, Aram Vosoughi, Hongzhi Xu, Xuefeng Wang, Xiaoqing Yu, Alice Yu, Logan Zemp, Scott M. Gilbert, Michael A. Poch, Wade J. Sexton, declare no conflict of interest; Philippe E. Spiess has no financial disclosures; only leadership role disclosure (nonfinancially compensated as NCCN Bladder and Penile Cancer Vice-chair);  Roger Li has received research support from Predicine, Veracyte, CG Oncology, Valar labs, Merck, and Janssen, serves as a consultant for BMS, Merck, Thericon, CG Oncology, and has honoraria from SAI MedPartners, Solstice Health Communications, Putnam Associates, UroToday, MJH Lifesciences","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Joshua Linscott, Hiroko Miyagi, Prithvi Murthy, Sijie Yao, G. Daniel Grass, Aram Vosoughi, Hongzhi Xu, Xuefeng Wang, Xiaoqing Yu, Alice Yu, Logan Zemp, Scott M. Gilbert, Michael A. Poch, Wade J. Sexton, declare no conflict of interest; Philippe E. Spiess has no financial disclosures; only leadership role disclosure (nonfinancially compensated as NCCN Bladder and Penile Cancer Vice-chair); Roger Li has received research support from Predicine, Veracyte, CG Oncology, Valar labs, Merck, and Janssen, serves as a consultant for BMS, Merck, Thericon, CG Oncology, and has honoraria from SAI MedPartners, Solstice Health Communications, Putnam Associates, UroToday, MJH Lifesciences.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}